FY2027 Earnings Forecast for Neogen Issued By Zacks Research

Neogen Corporation (NASDAQ:NEOG) – Equities researchers at Zacks Research increased their FY2027 earnings estimates for shares of Neogen in a research note issued on Thursday, August 20th. Zacks Research analyst Team now anticipates that the company will earn $0.25 per share for the year, up from their prior forecast of $0.21. The consensus estimate for Neogen’s current full-year earnings is $0.25 per share. Zacks Research also issued estimates for Neogen’s FY2029 earnings at $0.32 EPS.

A number of other brokerages have also weighed in on NEOG. Weiss Ratings raised Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Piper Sandler upgraded Neogen from a “neutral” rating to an “overweight” rating and raised their price target for the company from $13.00 to $14.00 in a research note on Wednesday. Finally, Wall Street Zen upgraded Neogen from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.00.

Neogen Stock Up 0.5%

Shares of NASDAQ:NEOG opened at $11.70 on Thursday. The business’s 50 day moving average is $10.37 and its 200 day moving average is $9.85. The stock has a market cap of $2.55 billion, a P/E ratio of -390.00, a price-to-earnings-growth ratio of 4.59 and a beta of 1.77. Neogen has a 52-week low of $4.90 and a 52-week high of $12.85. The company has a quick ratio of 2.91, a current ratio of 3.82 and a debt-to-equity ratio of 0.38.

Neogen (NASDAQ:NEOG) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm had revenue of $225.30 million during the quarter, compared to the consensus estimate of $212.35 million. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. The company’s revenue was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.82) earnings per share.

Institutional Trading of Neogen

A number of hedge funds have recently bought and sold shares of NEOG. BlackRock Inc. purchased a new stake in shares of Neogen during the second quarter valued at about $300,545,000. Cibc World Markets Corp purchased a new position in shares of Neogen in the 4th quarter worth approximately $47,983,000. T. Rowe Price Investment Management Inc. raised its stake in shares of Neogen by 249.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 8,181,768 shares of the company’s stock worth $57,191,000 after acquiring an additional 5,838,570 shares in the last quarter. Bamco Inc. NY purchased a new stake in Neogen during the second quarter valued at approximately $45,094,000. Finally, SG Americas Securities LLC lifted its position in Neogen by 287.4% during the first quarter. SG Americas Securities LLC now owns 6,266,033 shares of the company’s stock valued at $58,211,000 after acquiring an additional 4,648,436 shares during the last quarter. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Key Stories Impacting Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
• Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
• Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
• Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.